- February 18, 2021– Statistically Significant Decrease in Serum Alkaline Phosphatase (ALP) Levels in the Per-Protocol Population After 24-Week IMU-838 Treatment, as Compared…
- February 17, 2021– Clinical Activity of IMU-838 Confirmed Based on Multiple Secondary Endpoints, Including Clinically Meaningful Improvements in Time to Clinical Recovery…
- February 11, 2021NEW YORK, February 11, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
- January 5, 2021– Management Provides Update on Timing of Data for IMU-838 in Primary Sclerosing Cholangitis – NEW YORK, January 5, 2021 – Immunic,…
